femtoLUCENT™ PLUS-AP (6 Citations)
The femtoLUCENT™ PLUS-AP kit is based on alkaline phosphatase (AP) chemiluminescence reaction. The chemiluminescence light emission can be recorded by a short exposure to blue-light sensitive autoradiography films. The femtoLUCENT™ PLUS-AP kit allows for detection of femtogram quantity of antigens with no background. The kit reagents are sufficient for 25 mini blots (8.5 x 7.5 cm size).
In addition, femtoLUCENT™ PLUS-AP is also supplied in a kit format, containing our non-animal protein blocking agent (NAP BLOCKER™) and wash buffer (femto-TBST™). The femtoLUCENT™ PLUS-AP kits allow detection of low femtogram levels (10-15) of antigens with low noise (signal/background) ratio. The kit reagents are sufficient for 25 mini blots or 1,500cm2 of PVDF or nitrocellulose membrane. The trial size (Cat. # 786-10APT) is suitable for 5 mini blots or 300cm2.
For a complete chemiluminescence immunodetection system, we offer optional alkaline phosphatase (AP) conjugated secondary antibodies against mouse, rabbit, human, rat and goat.
Features
- Intense light emission with low background and high signal
- Supplied with a novel blocking agent to allow a rapid blocking step that produces a clear background
- Economical: greater value compared to similar products
Applications
- Quick and sensitive non-isotopic detection of proteins on transfer membranes (suitable for nitrocellulose & PVDF membranes)
- Immunodetection of proteins and antigens for Western blots and dot blot applications
- Low femtogram detection (10-15) that allows for detection of >10fg protein on a dot blot and >1pg on a Western blot
- Dahiya, Surbhi et al (2022) Protocol for investigating the biogenesis of SARS-CoV-2 S pseudoviruses in HEK293T cells transduced to express the virus-specific intrabodies. CELL PRESS. https://doi.org/10.1016/j.xpro.2022.101978
- Singh, Sudhakar et al (2022) Robust anti-SARS-CoV2 single domain antibodies ross neutralize multiple viruses. CELL PRESS. https://doi.org/10.1016/ j.isci.2022.104549
- Yin, X. et al. (2020) Span Pub. doi.org/10.3892/mmr.2020.11556
- Poria, D.K. et al (2015) Oncogene. doi: 10.1038/onc.2015.235
- Lin-Cereghino, G.P. et al (2013) Gene. 519:311
- Lam, D.H. et al (2012) Canad. J. Physiol Pharmacol. 90:435